Literature DB >> 7821162

Prevalence of arterial hypertension in diabetic patients before and after the JNC-V.

L Tarnow1, P Rossing, M A Gall, F S Nielsen, H H Parving.   

Abstract

OBJECTIVE: To compare the prevalence of arterial hypertension in patients with insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) according to blood pressure (BP) criteria from the World Health Organization (WHO) and The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V). RESEARCH DESIGN AND METHODS: Two cohorts of Caucasian patients attending the outpatient clinic at Hvidöre Hospital were identified: 1) 957 patients with IDDM; 53% men, 40 (18-75) years of age (mean [range]); and 2) 549 patients with NIDDM; 53% men, 60 (20-76) years of age. BP was measured at least yearly, while patients rested in a sitting position, with a standard clinical sphygmomanometer. Patients were classified as hyper- or normotensive based on average BP during a 3-year follow-up period. Patients receiving antihypertensive treatment were classified as hypertensives.
RESULTS: In IDDM patients, the prevalence of arterial hypertension rose from 15 to 42% in the normoalbuminuric group, from 26 to 52% in the microalbuminuric group, and from 61 to 79% in the macroalbuminuric group when WHO and JNC-V criteria were compared. The corresponding rises in NIDDM patients were from 51 to 71% (normo-), from 73 to 90% (micro-), and from 82 to 93% (macroalbuminuria). Of the untreated hypertensive patients, 78% of IDDM patients and 50% of NIDDM patients had stage 1 (140-159/90-99 mmHg) hypertension; 20% of IDDM patients and 37% of NIDDM patients had stage 2 (160-179/100-109 mmHg) hypertension. Two out of three untreated hypertensive patients had isolated systolic hypertension.
CONCLUSIONS: The new JNC-V criteria approved by the American Diabetes Association leads to a considerable increase in the prevalence of arterial hypertension in a population of IDDM and NIDDM patients. Isolated systolic hypertension contributes importantly.

Entities:  

Mesh:

Year:  1994        PMID: 7821162     DOI: 10.2337/diacare.17.11.1247

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  19 in total

Review 1.  Earlier management of subjects who are prone to hypertension and diabetes mellitus.

Authors:  Hiromi Rakugi; Toshio Ogihara
Journal:  Curr Diab Rep       Date:  2004-04       Impact factor: 4.810

Review 2.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

3.  An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study.

Authors:  A Y T Wu; N C T Kong; F A de Leon; C Y Pan; T Y Tai; V T F Yeung; S J Yoo; A Rouillon; M R Weir
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

4.  Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.

Authors:  L Tarnow; P Hildebrandt; B V Hansen; K Borch-Johnsen; H-H Parving
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

Review 5.  Benefit of Blood Pressure Control in Diabetic Patients.

Authors:  Ulrich Kintscher
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 6.  Diabetic nephropathy and extracellular matrix.

Authors:  S O Kolset; F P Reinholt; T Jenssen
Journal:  J Histochem Cytochem       Date:  2012-10-27       Impact factor: 2.479

Review 7.  Drug treatment of hypertension complicating diabetes mellitus.

Authors:  M J MacLeod; J McLay
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol.

Authors:  Manuel A Gómez-Marcos; José I Recio-Rodríguez; Emiliano Rodríguez-Sánchez; Yolanda Castaño-Sánchez; Angela de Cabo-Laso; Benigna Sánchez-Salgado; Carmela Rodríguez-Martín; Carmen Castaño-Sánchez; Leticia Gómez-Sánchez; Luis García-Ortiz
Journal:  BMC Public Health       Date:  2010-03-18       Impact factor: 3.295

Review 9.  Emerging understanding of roles for arterioles in inflammation.

Authors:  Ronen Sumagin; Ingrid H Sarelius
Journal:  Microcirculation       Date:  2013-11       Impact factor: 2.628

Review 10.  Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?

Authors:  Radica Alicic; Katherine R Tuttle
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.